Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"
![Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"](https://assets2.sharewise.com/attachment/file/58915/open-uri20170726-11705-1ssp7qi "Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"")
Biogen (NASDAQ: BIIB) started the biotech earnings season off with a bang, generating enough revenue for the company to have confidence to increase its revenue guidance for the year. Earnings weren't nearly as hot, but Biogen has a good excuse: one-time investments in the company's future that lowered the bottom-line results. Beyond the profit-loss statement, Biogen laid out plans for diversifying away from its multiple sclerosis (MS) franchise as it looks to accelerate growth.
Metric
Q2 2017
Source: Fool.com
Bristol-Myers Squibb Aktie
43,94 €
-2,27 %
Die Community zeigt leichtes Interesse an Bristol-Myers Squibb mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 65 € für Bristol-Myers Squibb impliziert eine deutliche Steigerung um über 20% gegenüber 43.94 €.
